Abiopharma

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Events and transactions

BeOne Medicinesの基盤となる血液疾患領域フランチャイズ、EHA 2026でB細胞がんイノベーションの新時代を先導

Supplementary report to the meeting convening notice report to be held on 15.7.26

La division hématologique phare de BeOne Medicines ouvre la voie à une nouvelle ère d’innovation dans le traitement des cancers à cellules B lors du congrès EHA 2026

Trustee report for the company’s BONDS Series 1 for 2025, Mishmeret

Invitation to a special meeting on 22.7.26 – arrangement for delimiting activity with BIG Shopping Centers – voting ballot

Register of shareholders, changes and capital status – exercise of employee warrants